Tin tức & Cập nhật

Twice-yearly subcutaneous (SC) lenacapavir demonstrates high efficacy, favourable safety, and consistent pharmacokinetics (PK) as pre-exposure prophylaxis (PrEP) for HIV-negative youth (aged 16–25 years) in an analysis of the phase III PURPOSE 1 (P1) and PURPOSE 2 (P2) trials.

A recent Singapore study has identified several factors, such as Autism Diagnostic Observation Schedule (ADOS) score and race, that can predict intellectual impairment among children with autism spectrum disorder (ASD).